IF: 1.578
Cite Score:
1.45
THOMSON REUTERS - SCOPUS

Adefovir as a Novel Drug for the Treatment of Chronic Hepatitis B in Patients with End-Stage Renal Disease and Kidney Recipients

AUTHORS

Seyed Mohammadmehdi Hosseini Moghaddam 1 , * , Elham Iran Pour 2

1 Urology and Nephrology Research Center (UNRC), Shahid Beheshti University, M.C., h_sasan@hotmail.com, IR-Iran

2 Urology and Nephrology Research Center (UNRC), Shahid Beheshti University, M.C., IR-Iran

How to Cite: Hosseini Moghaddam S, Pour E. Adefovir as a Novel Drug for the Treatment of Chronic Hepatitis B in Patients with End-Stage Renal Disease and Kidney Recipients, Hepat Mon. Online ahead of Print ; 8(2):135-139.

ARTICLE INFORMATION

Hepatitis Monthly: 8 (2); 135-139
Article Type: Review Article
Received: December 16, 2007
Accepted: May 20, 2008

Crossmark

CHEKING

READ FULL TEXT
Abstract

Administration of adefovir dipivoxil (ADV) has been shown to provide an increased rate of hepatitis Be (HBe) seroconversion. It is also effective in the treatment of HIV. Because of its significant nephrotoxicity after 24 weeks of the treatment, this drug is no longer used for management of HIV. However, hepatitis B virus is inhibited with lower doses of ADV. The drug can even be used safely in those with renal impairment. This review provides new aspects of treatment of hepatitis B using ADV, especially in patients with renal dysfunction as well as renal transplant recipients. We showed that ADV can be used as a safe drug in renal transplant recipients.

Keywords

Adefovir Hepatitis B Kidney Transplantation Renal Failure

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: